Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Checkpoint Therapeutics Inc (CKPT)

Checkpoint Therapeutics Inc (CKPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates GlobeNewswire - Tue Nov 12, 3:30PM CST

FBIO : 1.4300 (-8.92%)
CKPT : 3.43 (-9.26%)
10 Stocks Retailers On Stocktwits Are Most Bullish/Bearish About To Start The Week Stocktwits - Mon Nov 11, 2:32AM CST

As the new week unfolds, earnings and economic data will again dictate sentiment.

MARA : 21.07 (+1.35%)
BLK : 1,047.37 (+0.03%)
NFLX : 823.96 (-1.59%)
PDD : 114.00 (+1.49%)
AUPH : 8.12 (-2.52%)
CKPT : 3.43 (-9.26%)
EVH : 12.38 (-2.29%)
EBS : 7.72 (-16.72%)
BIDU : 84.58 (+0.62%)
SPY : 585.78 (-1.28%)
COIN : 305.85 (+9.69%)
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma Globe Newswire - Thu Jun 16, 2022

Objective response rate of 54.8% in patients with locally advanced cSCC, a potential 2nd indication for cosibelimabPreviously met primary endpoint in...

CKPT : 3.43 (-9.26%)
Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire - Mon Jun 6, 2022

WALTHAM, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted...

CKPT : 3.43 (-9.26%)
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference Globe Newswire - Thu May 19, 2022

WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted...

CKPT : 3.43 (-9.26%)
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency Globe Newswire - Fri May 13, 2022

Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in Europe...

CKPT : 3.43 (-9.26%)
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Globe Newswire - Thu May 12, 2022

Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA...

CKPT : 3.43 (-9.26%)
Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities Globe Newswire - Mon Apr 4, 2022

WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and...

CKPT : 3.43 (-9.26%)
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Globe Newswire - Mon Mar 28, 2022

WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and...

CKPT : 3.43 (-9.26%)
2 Biotech Stocks That Could Be 10-Baggers in 2022 Motley Fool - Wed Jan 26, 2022

These two clinical-stage biotechs have major upcoming catalysts that could catapult their shares higher.

AXSM : 93.17 (-4.31%)
CKPT : 3.43 (-9.26%)

Barchart Exclusives

Is Domino's Pizza Stock Worth Buying? Buffett Likes Its Huge Free Cash Flow Barchart - Fri Nov 15, 12:49PM CST
Berkshire Hathaway's new stake in Domino's Pizza stock shows that its huge free cash flow (FCF) and FCF margins are attracting value investors. Shorting out-of-the-money DPZ puts is one way to play this. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot